ENLIVEN THERAPEUTICS INC

Enliven Therapeutics CFO sells 5,018 shares, raising questions about insider confidence amid a 14.9% monthly rise.

Enliven Therapeutics sees a strategic insider sell‑off amid a 110% YTD rally, prompting investors to weigh profit‑taking risks against a strong kinase‑inhibitor pipeline.

Insider sales at Enliven Therapeutics reveal a disciplined plan‑based strategy amid a rally—what it means for investors and future moves.

Enliven Therapeutics’ CMO buys and sells shares, signaling strong confidence in the company’s oncology pipeline and a potential upside in valuation.

Enliven Therapeutics CMO buys shares at $2.48—insider buying that reflects tax‑advantaged planning, not bullish sentiment, amid the company’s negative earnings and modest P/E.

Enliven Therapeutics insider sale: CFO Benjamin Hohl sells 10,000 shares—analyzing the move’s impact on stock value, investor confidence, and future prospects.

Enliven insider sale: Heyman sells 1,230 shares at $26.18 in a volatile market—what this means for investors and the company’s future.

Enliven Therapeutics insider sale: CSO Joseph Lyssikatos sells 5,000 shares at $29.04, reflecting a planned, disciplined move that signals confidence without impacting the company’s growth prospects.

Enliven COO Patel Anish’s 10b5‑1 sale: 48,057 shares at $27.98—why insider trading amid a 70% rally matters for investors.

Enliven Therapeutics’ chief scientist sold $2.4 m in shares, a routine 10b5‑1 plan that shows cash‑flow discipline, not panic, while keeping large long‑term stakes.